Eli Lilly’s Olumiant (baricitinib) Receives FDA’s Fast Track Designation for Systemic Lupus Erythematosus (SLE)

 Eli Lilly’s Olumiant (baricitinib) Receives FDA’s Fast Track Designation for Systemic Lupus Erythematosus (SLE)

Eli Lilly’s Olumiant (baricitinib) Receives FDA’s Fast Track Designation for Systemic Lupus Erythematosus (SLE)

Shots:
  • The FDA’s designation is based on P-II study results assessing Baricitinib in patients with SLE,
    presented at European Congress of Rheumatology 2018
  • Lilly is also evaluating baricitinib’s two doses in P-III SLE trials and for moderate-to -severe atopic dermatitis, with its expected results in H1’19
  • Olumiant (baricitinib) 2mg is an inhibitor of janus kinase, further blocking its subtypes JAK1 and JAK2 and is approved in 50 countries for adults with rheumatoid arthritis

 Click here to read full press release/ article | Ref: Eli Lilly | Image:  iStock

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post